Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Interpace Diagnostics announces $4.2m registered direct offering of common stock

Published 04 January 2017

Interpace Diagnostics Group, a company that provides clinically useful molecular diagnostic tests and pathology services, announced that it has entered into a securities purchase agreement with certain institutional investors.

The deal has been signed to purchase an aggregate of 375,000 shares of common stock at a price of $6.75 per share and an aggregate of 255,000 pre-funded warrants to purchase common stock, at a purchase price of $6.74 per share, with $0.01 per share payable upon exercise of each pre-funded warrant, in a registered direct offering with aggregate gross proceeds of approximately $4.2 million. 

 The offering is expected to close on or about January 6, 2017, subject to the satisfaction of customary closing conditions.

Maxim Group LLC acted as exclusive placement agent for the offering.

After deducting the placement agent's commission and other estimated offering expenses payable by Interpace, the net proceeds to Interpace are anticipated to be approximately $3.7 million. 

Interpace intends to use the net proceeds of the offering for working capital, repayment of indebtedness and general corporate purposes.

The securities described above are being offered under the Company's shelf registration statement on Form S-3 (No. 333-207263), including a base prospectus, previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC).

The securities will be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement.

Interpace provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management.

The Company currently has three commercialized molecular tests: PancraGen®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay.

Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.



Source: Company Press Release